The JSE and finance forum for South Africa
General Category => Shares => Topic started by: Camleaver on February 09, 2017, 04:25:13 pm
-
Hi Everybody,
Any idea what's happening with ASC? with it's current drop in share price?
Would you be buying more at these levels?
Thanks
-
I have a order in for 1900 if it hits that I enter.
-
ASC has great potential. The Scitec and Remedica acquisitions will for the first time contribute to earnings when the next results are released. Forward PE maybe high teens.
Unlike drug companies that are constantly being pressurised or forced to cut their prices by governments, ASC products are mainly generic, over the counter, veterinary and nutrition/sports nutrition. Yup you can't fight governments and win - see the Trump effect on drug companies and biotech companies, or how co-payments in UAE have hit Mediclinic (with Switzerland contemplating levies).
So I reckon wait for the results, although a buy at these levels would not give me sleepless nights.
-
ASC = 2499 Up 12.31% in a week. Still not where I bought @ 2550, but watch this space.
-
Urgh, it never got to where I wanted, to late to jump in?
Do you see this stock going beyond R10?
-
Do you see this stock going beyond R10?
It is already way beyond that, but you meant R100 not so ?
If so, it will all depend on the timeframe. I have no idea but would not rule out ± R30 by end 2017.
(Sunwave Pharma SRL and NHP Pharma LTD are the most recent acquisitions).
The Sunwave Transaction and the NHP Pharma Transaction are collectively referred to as
the “Proposed Transactions” for the purpose of this announcement.
Sunwave is a distributor of complementary and alternative medicines (“CAMS”) and food
supplement products in Romania. It is the largest player in the food supplements category
and sixth largest player in the broader over-the-counter (“OTC”) category in the country. The
company specialises in marketing its products directly to the doctor community, through a
sales force of approximately 290 effective and well-trained individuals.
NHP Pharma, in collaboration with its third-party suppliers, has developed a vast product
portfolio of complementary medicines across nine major therapeutic areas. The efficacy of its
products have been further validated through clinical and post-marketing studies. NHP
Pharma owns the trademarks and other relevant IP relating to its products, with Sunwave
being NHP Pharma’s largest customer.
The Proposed Transactions are inter-conditional and, going forward, will be treated as a
single business combination in the hands of Ascendis. Ascendis aims to achieve an EBITDA
margin of approximately 20% from the Proposed Transactions.
-
Sorry about that, correct I meant R100 ie will they join the other health and pharma stocks one day. (5 years)
-
Forward PE will come down to high teens.
http://www.sharenet.co.za/v3/quickshare.php?scode=ASC